We went to the U.S. Patent & Trademark Office to get the lowdown on the CRISPR gene-editing patent dispute. Read C&EN’s coverage here:Ìý
CRISPR/Cas9 is making gene-editing cheaper and easier than ever before, but the creators are embroiled in a fierce dispute over who holds the patents to CRISPR technology. In this episode, after hearing attorneys duke it out, Ryan Cross explains how the kerfuffle developed, and what the possible outcomes of the impending decision mean.
If this episode makes you crazy for more CRISPR, check out these great resources.
Expanding CRISPR toolkit may render patent fight moot | C&EN
The CRISPR craze continued | C&EN
Genome Editing Writ Large | C&EN
A simple guide to CRISPR, one of the biggest science stories of 2016 | Vox
The unsung heroes of CRISPR | Nature
One of our reporters tried to do CRISPR. He failed miserably. | Science
Who Owns the Biggest Biotech Discovery of the Century? | MIT Technology Review
.
Speaking of ChemistryÌýis brought to you byÌýChemical & Engineering News, the news magazine of the American Chemical Öйú365betÖÐÎĹÙÍø.
;void(0);){kind=link}